moneyheap
IONS · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Ionis Pharmaceuticals, Inc. Common Stock (IONS) stock moving?
IONS fell from a $39.42 close on Nov 6 to $28.19 on Nov 10, about 28.5% lower, after the Q3 2026 report on Nov 9. Volume hit 19.5M shares that day versus roughly 3.3M per day in the prior week, and another 10.7M traded on Nov 10 as the stock kept selling off, so the move was heavy and still active. The quarter itself beat estimates: revenue was $243M versus $182M expected, and adjusted EPS was $(0.40) versus $(1.21). The market focused on the cut to 2026 TRYNGOLZA sales guidance, as the sHTG launch is ramping more slowly than expected, and on full-year total revenue guidance of $875M-$900M, which was reaffirmed but sits below the $916M consensus. Other negatives include Novartis dropping pelacarsen, a heart drug Ionis discovered, on Nov 8, and a law firm opening a securities investigation on Nov 9. Analysts kept their ratings but cut targets: Goldman Sachs has Neutral at $41, while Morgan Stanley, Wells Fargo, Oppenheimer, RBC, TD Cowen and HC Wainwright remain Buy-rated with targets from $53 to $80. Supportive points include the first approval of ZANVASTRO for Alexander disease, GSK's Hibsago approvals in the US and Canada, reaffirmed DAWNZERA product revenue guidance, and the company's stated pipeline of near-term partnered approvals. The stock now sits near its 52-week low, and the next catalysts are investor conferences in November and December.
News behind the analysis
- Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?Shares hit a 52-week low after Ionis cut its 2026 TRYNGOLZA sales guidance by about half, despite beating Q3 estimates and posting 55% revenue growth.
- Ionis Pharmaceuticals Reports Third Quarter 2026 Financial ResultsIonis reported Q3 2026 revenue of $243.0 million, with ZANVASTRO approved for Alexander disease and TRYNGOLZA 2026 product sales guidance lowered.
- Ionis Pharmaceuticals Q3 Adj. EPS $(0.40) Beats $(1.21) Estimate, Sales $243.000M Beat $182.117M EstimateThird-quarter adjusted EPS and revenue both came in well above analyst estimates.
- Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $916.396M EstIonis reaffirmed full-year 2026 total revenue guidance, which sits below the $916.4 million analyst estimate.
- Novartis Discontinues Development of Pelacarsen for Atherosclerotic Cardiovascular DiseaseNovartis decided to abandon pelacarsen, a heart disease therapy discovered by Ionis, after a late-stage trial setback.
- Kehoe Law Firm Investigates Ionis Pharmaceuticals Following Sales Guidance CutKehoe Law Firm opened an investigation into potential securities claims after the downward revision of the 2026 TRYNGOLZA sales forecast.
- Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $41Goldman Sachs kept a Neutral rating and cut its price target to $41, the lowest target among the reported updates.
- Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $75Morgan Stanley kept its Overweight rating and lowered its price target to $75.
- Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $80Wells Fargo kept its Overweight rating and cut its price target to $80, the highest target among the reported updates.
About Ionis Pharmaceuticals, Inc. Common Stock
Ionis Pharmaceuticals is a Carlsbad, California biotech that pioneered antisense oligonucleotide drugs, which target RNA to switch off disease-causing proteins in neurological, cardiometabolic and rare diseases. After decades of mostly licensing its drugs to big pharma partners, it is now launching medicines on its own, including TRYNGOLZA (olezarsen), DAWNZERA and ZANVASTRO for Alexander disease.
How it makes money
It earns revenue in two main ways. The first is commercial revenue: sales of its own drugs (TRYNGOLZA and DAWNZERA) plus royalties on partnered drugs such as Biogen's SPINRAZA. The second is R&D revenue: upfront, milestone and licensing payments from partners such as Roche, AstraZeneca, Biogen and Novartis. Revenue was about $514M in the first half of 2026, up roughly 69% from a year earlier once one-time payments are excluded. The company still runs an operating loss as it pays for its launches, and it is targeting cash-flow breakeven around 2028.
What usually moves IONS
- TRYNGOLZA launch sales and FDA decision on its expansion to severe hypertriglyceridemia (very high blood fats)
- Results from late-stage clinical trials
- FDA approvals and new drug launches
- Milestone payments and royalties from partners
- Cash burn and progress toward profitability